Caredx Inc Stock
€17.43
Your prediction
Caredx Inc Stock
CareDx is a publicly traded biotechnology company that specializes in providing innovative transplant solutions for patients suffering from various diseases. The company has developed a range of diagnostic solutions that help doctors monitor the health of organ transplant recipients, including tests that can detect early signs of organ rejection. CareDx has a strong track record of developing cutting-edge medical technologies and working with leading healthcare providers to improve patient outcomes. As a publicly-listed company, CareDx has a diverse shareholder base and is subject to the scrutiny of regulatory bodies, providing transparency and accountability to investors.
Pros and Cons of Caredx Inc in the next few years
Pros
Cons
Performance of Caredx Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Caredx Inc | 1.210% | 0.490% | 6.736% | -23.080% | 6.801% | 13.595% | -75.979% |
| Evolus Inc | -1.940% | -0.980% | -29.123% | -67.419% | -25.872% | -53.563% | -28.343% |
| Madrigal Pharmaceuticals inc. | -2.190% | -1.827% | -19.416% | 29.159% | -18.074% | 54.697% | 341.418% |
| Heron Therapeutics Inc. | -1.610% | -2.732% | 8.796% | -28.658% | 5.476% | -55.416% | -92.260% |
News
CareDx's CEO Conducts Multiple Sale of Shares Towards the End of January 2026
John Walter Hanna Jr., President and CEO of CareDx (NASDAQ:CDNA), directly sold 19,480 shares in multiple open-market transactions on Jan. 21 and Jan. 22, 2026, for a total value of approximately
CareDx President and CEO Sells 19,000 Shares for $412,000
John Hanna, President and CEO of CareDx (NASDAQ:CDNA), directly sold 19,480 shares in multiple open-market transactions on Jan. 21, 2026 and Jan. 22, 2026, with an aggregate transaction value of
CareDx (CDNA) EPS Beats Sales Gain 14%
CareDx (NASDAQ:CDNA), a molecular diagnostics company specializing in transplant care solutions, released its results for the second quarter of fiscal 2025 on August 6, 2025. The big news from the


